[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631303":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":18,"locations":10,"responsibleParty":24,"collaborators":10,"id":28,"slug":29,"hasResults":30,"nctId":31,"briefTitle":32,"officialTitle":33,"acronym":10,"eligibilityCriteria":34,"healthyVolunteers":30,"sex":35,"minAge":10,"maxAge":10,"enrollmentInfo":36,"targetDuration":10,"studyType":39,"phases":10,"briefSummary":40,"conditions":41,"keywords":10,"overallStatus":45,"whyStopped":10,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":10},{"fullName":5,"class":6},"Peking Union Medical College Hospital","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"GM group",null,[12],"Other: Gut microbiome analysis",[14],{"type":6,"name":15,"description":16,"armGroupLabels":17,"otherNames":10},"Gut microbiome analysis","Gut microbiome analysis would be performed before and after glofitamab treatment in DLBCL patients.",[9],[19],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},"Jing Ruan","CONTACT","+8615201435860","15201435860@163.com",{"type":25,"investigatorFullName":26,"investigatorTitle":27,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Ruanjing","Dr","100631303","gut-microbiome-in-dlbcl-treated-with-glofitamab-100631303",false,"NCT07498920","Gut Microbiome in DLBCL Treated With Glofitamab","Role of the Gut Microbiome in the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated With Glofitamab","Inclusion Criteria:\n\n1. Histologically\u002Fcytologically confirmed diagnosis of DLBCL\n2. Is being planned to received Glofitamab\n3. Be able to provide written informed consent\n\nExclusion Criteria:\n\n1. Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results.\n2. Concurrent second malignancy.","ALL",{"count":37,"type":38},30,"ESTIMATED","OBSERVATIONAL","The gut microbiome (GM) has recently emerged as one of the key modifiable factors of response and prognosis to immunotherapy in cancer patients. Currently, it is unknown if GM also modulates anti-tumor responses to T cell engagers (TCE) including glofitamab in DLBCL patients.",[42,43,44],"DLBCL","Glofitamab","Gut Biome","NOT_YET_RECRUITING","2026-03-23",{"date":48,"type":49},"2026-03-27","ACTUAL",{"date":51,"type":38},"2026-04-01",{"date":53,"type":38},"2029-12-31",{"name":5,"class":6}]